Reference(s)
Click here to return to the Reference Table

Category: Carcinomas
Descriptor: Reviews


Reference Number: 736
Cañadas I, Rojo F, Arumí-Uría M, Rovira A, Albanell J, Arriola E. C-MET as a new therapeutic target for the development of novel anticancer drugs. Clin Transl Oncol. 12, 253-60 (2010)
PubMed link      E-mail link

Reference Number: 738
Goetsch L, Caussanel V. Selection criteria for c-Met-targeted therapies: emerging evidence for biomarkers. Biomark Med. 4, 149-70 (2010)
PubMed link      E-mail link

Reference Number: 739
Cecchi F, Rabe DC, Bottaro DP. Targeting the HGF/Met signalling pathway in cancer. Eur J Cancer. 46, 1260-70 (2010)
PubMed link      E-mail link

Reference Number: 743
Liu X, Newton RC, Scherle PA. Developing c-MET pathway inhibitors for cancer therapy: progress and challenges. Trends Mol Med. 16, 37-45 (2010)
PubMed link      E-mail link

Reference Number: 744
Martin TA, Jiang WG. Hepatocyte growth factor and its receptor signalling complex as targets in cancer therapy. Anticancer Agents Med Chem. 10, 2-6 (2010)
PubMed link      E-mail link

Reference Number: 745
Underiner TL, Herbertz T, Miknyoczki SJ. Discovery of small molecule c-Met inhibitors: Evolution and profiles of clinical candidates. Anticancer Agents Med Chem. 10, 7-27 (2010)
PubMed link      E-mail link

Reference Number: 747
Michieli P. Hypoxia, angiogenesis and cancer therapy: to breathe or not to breathe? Cell Cycle. 8, 3291-6 (2009)
PubMed link      E-mail link

Reference Number: 748
Lai AZ, Abella JV, Park M. Crosstalk in Met receptor oncogenesis. Trends Cell Biol. 19, 542-51 (2009)
PubMed link      E-mail link

Reference Number: 749
Boccaccio C, Comoglio PM. Genetic link between cancer and thrombosis. J Clin Oncol. 27, 4827-33 (2009)
PubMed link      E-mail link

Reference Number: 753
Dussault I, Bellon SF. From concept to reality: the long road to c-Met and RON receptor tyrosine kinase inhibitors for the treatment of cancer. Anticancer Agents Med Chem. 9, 221-9 (2009)
PubMed link      E-mail link

Reference Number: 754
You WK, McDonald DM. The hepatocyte growth factor/c-Met signaling pathway as a therapeutic target to inhibit angiogenesis. BMB Rep. 41, 833-9 (2008)
PubMed link      E-mail link

Reference Number: 757
Matsumoto K, Nakamura T, Sakai K, Nakamura T. Hepatocyte growth factor and Met in tumor biology and therapeutic approach with NK4. Proteomics. 8, 3360-70 (2008)
PubMed link      E-mail link

Reference Number: 758
Liu X, Yao W, Newton RC, Scherle PA. Targeting the c-MET signaling pathway for cancer therapy. Expert Opin Investig Drugs. 17, 997-1011 (2008)
PubMed link      E-mail link

Reference Number: 759
Comoglio PM, Giordano S, Trusolino L. Drug development of MET inhibitors: targeting oncogene addiction and expedience. Nat Rev Drug Discov. 7, 504-16 (2008)
PubMed link      E-mail link

Reference Number: 761
Abidoye O, Murukurthy N, Salgia R. Review of clinic trials: agents targeting c-Met. Rev Recent Clin Trials. 2, 143-7 (2007)
PubMed link      E-mail link

Reference Number: 762
Dussault I, Bellon SF. c-Met inhibitors with different binding modes: two is better than one. Cell Cycle. 7, 1157-60 (2008)
PubMed link      E-mail link

Reference Number: 763
Knudsen BS, Vande Woude G. Showering c-MET-dependent cancers with drugs. Curr Opin Genet Dev. 18, 87-96 (2008)
PubMed link      E-mail link

Reference Number: 764
Migliore C, Giordano S. Molecular cancer therapy: can our expectation be MET? Eur J Cancer. 44, 641-51 (2008)
PubMed link      E-mail link

Reference Number: 765
Gentile A, Trusolino L, Comoglio PM. The Met tyrosine kinase receptor in development and cancer. Cancer Metastasis Rev. 27, 85-94 (2008)
PubMed link      E-mail link

Reference Number: 767
Matsumoto K, Nakamura T. NK4 gene therapy targeting HGF-Met and angiogenesis. Front Biosci. 13, 1943-51 (2008)
PubMed link      E-mail link

Reference Number: 768
Lesko E, Majka M. The biological role of HGF-MET axis in tumor growth and development of metastasis. Front Biosci. 13, 1271-80 (2008)
PubMed link      E-mail link

Reference Number: 769
Tulasne D, Foveau B. The shadow of death on the MET tyrosine kinase receptor. Cell Death Differ. 15, 427-34 (2008)
PubMed link      E-mail link

Reference Number: 770
Desiderio MA. Hepatocyte growth factor in invasive growth of carcinomas. Cell Mol Life Sci. 64, 1341-54 (2007)
PubMed link      E-mail link

Reference Number: 771
Lengyel E, Sawada K, Salgia R. Tyrosine kinase mutations in human cancer. Curr Mol Med. 7, 77-84 (2007)
PubMed link      E-mail link

Reference Number: 772
Sattler M, Salgia R. c-Met and hepatocyte growth factor: potential as novel targets in cancer therapy. Curr Oncol Rep. 9, 102-8 (2007)
PubMed link      E-mail link

Reference Number: 773
Peruzzi B, Bottaro DP. Targeting the c-Met signaling pathway in cancer. Clin Cancer Res. 12, 3657-60 (2006)
PubMed link      E-mail link

Reference Number: 776
Dietrich S, Uppalapati R, Seiwert TY, Ma PC. Role of c-MET in upper aerodigestive malignancies--from biology to novel therapies. J Environ Pathol Toxicol Oncol. 24, 149-62 (2005)
PubMed link      E-mail link

Reference Number: 777
Corso S, Comoglio PM, Giordano S. Cancer therapy: can the challenge be MET? Trends Mol Med. 11, 284-92 (2005)
PubMed link      E-mail link

Reference Number: 778
Christensen JG, Burrows J, Salgia R. c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention. Cancer Lett. 225, 1-26 (2005)
PubMed link      E-mail link

Reference Number: 779
Wickramasinghe D, Kong-Beltran M. Met activation and receptor dimerization in cancer: a role for the Sema domain. Cell Cycle. 4, 683-5 (2005)
PubMed link      E-mail link

Reference Number: 780
Gao CF, Vande Woude GF. HGF/SF-Met signaling in tumor progression. Cell Res. 15, 49-51 (2005)
PubMed link      E-mail link

Reference Number: 781
Hammond DE, Carter S, Clague MJ. Met receptor dynamics and signalling. Curr Top Microbiol Immunol. 286, 21-44 (2004)
PubMed link      E-mail link

Reference Number: 782
Jiang WG, Martin TA, Parr C, Davies G, Matsumoto K, Nakamura T. Hepatocyte growth factor, its receptor, and their potential value in cancer therapies. Crit Rev Oncol Hematol. 53, 35-69 (2005)
PubMed link      E-mail link

Reference Number: 784
Gentile A, Comoglio PM. Invasive growth: a genetic program. Int J Dev Biol. 48, 451-6 (2004)
PubMed link      E-mail link

Reference Number: 787
Birchmeier C, Birchmeier W, Gherardi E, Vande Woude GF. Met, metastasis, motility and more. Nat Rev Mol Cell Biol. 4, 915-25 (2003)
PubMed link      E-mail link

Reference Number: 789
Ohnishi T, Daikuhara Y. Hepatocyte growth factor/scatter factor in development, inflammation and carcinogenesis: its expression and role in oral tissues. Arch Oral Biol. 48, 797-804 (2003)
PubMed link      E-mail link

Reference Number: 791
Ma PC, Maulik G, Christensen J, Salgia R. c-Met: structure, functions and potential for therapeutic inhibition. Cancer Metastasis Rev. 22, 309-25 (2003)
PubMed link      E-mail link

Reference Number: 792
Matsumoto K, Nakamura T. NK4 (HGF-antagonist/angiogenesis inhibitor) in cancer biology and therapeutics. Cancer Sci. 94, 321-7 (2003)
PubMed link      E-mail link

Reference Number: 793
Zhang YW, Vande Woude GF. HGF/SF-met signaling in the control of branching morphogenesis and invasion. J Cell Biochem. 88, 408-17 (2003)
PubMed link      E-mail link

Reference Number: 825
Trusolino L, Bertotti A, Comoglio PM. MET signalling: principles and functions in development, organ regeneration and cancer. Nat Rev Mol Cell Biol. 11, 834-48 (2010)
PubMed link      E-mail link

Reference Number: 858
Qian F, Engst S, Yamaguchi K, Yu P, Won KA, Mock L, Lou T, Tan J, Li C, Tam D, Lougheed J, Yakes FM, Bentzien F, Xu W, Zaks T, Wooster R, Greshock J, Joly AH. Inhibition of tumor cell growth, invasion, and metastasis by EXEL-2880 (XL880, GSK1363089), a novel inhibitor of HGF and VEGF receptor tyrosine kinases. Cancer Res. 69, 8009-16 (2009)
PubMed link      E-mail link

Reference Number: 889
To CT, Tsao MS. The roles of hepatocyte growth factor/scatter factor and met receptor in human cancers (Review). Oncol Rep. 5, 1013-24 (1998)
PubMed link      E-mail link

Reference Number: 963
Zhang YW, Graveel C, Shinomiya N, Vande Woude GF. Met decoys: will cancer take the bait? Cancer Cell. 6, 5-6 (2004)
PubMed link      E-mail link

Reference Number: 970
Cañadas I, Rojo F, Arumí-Uría M, Rovira A, Albanell J, Arriola E.  C-MET as a new therapeutic target for the development of novel anticancer drugs. Clin Transl Oncol. 12, 253-60 (2010)

PubMed link      E-mail link

Reference Number: 982
Vande Woude GF, Jeffers M, Cortner J, Alvord G, Tsarfaty I, Resau J. Met-HGF/SF: tumorigenesis, invasion and metastasis. Ciba Found Symp. 212, 119-30; discussion 130-2, 148-54 (1997)
PubMed link      E-mail link

Reference Number: 984
Jeffers M, Rong S, Woude GF. Hepatocyte growth factor/scatter factor-Met signaling in tumorigenicity and invasion/metastasis. J Mol Med (Berl). 74, 505-13 (1996)
PubMed link      E-mail link

Reference Number: 1071
Shinomiya N, Vande Woude GF. Suppression of met expression: a possible cancer treatment. Commentary re: S. J. Kim et al., reduced c-Met expression by an adenovirus expressing a c-Met ribozyme inhibits tumorigenic growth and lymph node metastases of PC3-LN4 prostate tumor cells in an orthotopic nude mouse model. Clin. Cancer Res., 14: 5161-5170, 2003. Clin Cancer Res. 9, 5085-90 (2003)
PubMed link      E-mail link

Reference Number: 1098
Liu X, Newton RC, Scherle PA. Development of c-MET pathway inhibitors. Expert Opin Investig Drugs. 20, 1225-41 (2011)
PubMed link      E-mail link

Reference Number: 1211
Comoglio PM, Giordano S, Trusolino L. Drug development of MET inhibitors: targeting oncogene addiction and expedience. Nat Rev Drug Discov. 7, 504-16 (2008)
PubMed link      E-mail link

Reference Number: 1260
Benvenuti S, Comoglio PM. The MET receptor tyrosine kinase in invasion and metastasis. J Cell Physiol. 213, 316-25 (2007)
PubMed link      E-mail link

Reference Number: 1371
Scagliotti GV, Novello S, von Pawel J. The emerging role of MET/HGF inhibitors in oncology. Cancer Treat Rev. 39, 793-801 (2013)
PubMed link      E-mail link

Reference Number: 1438
Yano S1, Nakagawa T. The current state of molecularly targeted drugs targeting HGF/Met. Jpn J Clin Oncol. 44, 9-12 (2014)
PubMed link      E-mail link

Reference Number: 1751
Heynen GJ, Fonfara A, Bernards R. Resistance to targeted cancer drugs through hepatocyte growth factor signaling. Cell Cycle. 13, 3808-17 (2014)
PubMed link      E-mail link